Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

in the fourth quarter of 2007, compared to $38.1 million in the fourth quarter of 2006. Research and development expenses totaled $149.5 million in the full year ended December 31, 2007, compared to $103.4 million in the full year ended December 31, 2006. The increase in research and development expenses in 2007 over 2006 is primarily attributable to clinical development costs for Arena's Phase 3 clinical program for lorcaserin, its drug candidate for the treatment of obesity, and a Phase 2a clinical trial of APD125, its drug candidate for the treatment of insomnia, as well as an increase in the number of its research and development personnel. Research and development expenses in 2007 included $4.2 million in non-cash, share-based compensation expense, compared to $2.9 million in 2006. General and administrative expenses totaled $6.9 million in the fourth quarter of 2007, compared to $5.2 million in the fourth quarter of 2006. General and administrative expenses totaled $26.6 million in the full year ended December 31, 2007, compared to $18.5 million in the full year ended December 31, 2006. The increase in general and administrative expenses in 2007 over 2006 is primarily attributable to an increase in Arena's general and administrative personnel and non-cash, share-based compensation expense, as well as costs related to Arena's growing and maturing patent portfolio. General and administrative expenses in 2007 included $4.6 million in non-cash, share-based compensation expense, compared to $2.1 million in 2006. Total patent costs, including patent costs related to partnered programs, were $6.4 million in the full year ended December 31, 2007, compared to $4.5 million in the full year ended December 31, 2006.

Cash, cash equivalents and short-term investments totaled $398.2 million at December 31, 2007, and included net proceeds of $103.2 million from a public offering completed in November 2007. Approximately 72.3 million shares of Arena's common stock were
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 DuPont ... plans to more than double the acreage contracted ... geographies supplying its soybean crush facility in Salisbury, ... this program will target several markets including foodservice ... with good performance. , For the 2015 growing ...
(Date:10/25/2014)... This research report “Biodegradable Plastics Market by ... Cellulose, PCL), by Application (Packaging, Fibers, Agriculture, Injection ... defines and segments the global biodegradable plastics market ... volume and value. , Browse 75 Market Data ... and in-depth TOC on “Biodegradable Plastics Market by ...
(Date:10/25/2014)... 24, 2014 SonaCare Medical, LLC, ... (HIFU) technology, announced that its Board of Directors ... Executive Officer, President and member of the Board ... will take-on expanded responsibilities within the company, including ... as overseeing commercialization, manufacturing and finance. , ...
(Date:10/25/2014)... Barrington, MA (PRWEB) October 25, 2014 ... control products, is pleased to announce the release ... achieve the highest level of contamination containment in ... ISO Class 3 and higher cleanroom environments, ValuSeal® ... filament polyester knit laundered wiper that continues Berkshire’s ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2
... Comprehensive tutorials ... use these invaluable resources. , ... Seattle, WA (PRWEB) July 16, 2009 -- OpenHelix today announced the availability of new ... The dbGaP resource is a database of genotypes and phenotypes with extensive ...
... , PHILADELPHIA and LONDON, July 15 ... leading provider of biopharmaceutical institutional research. Thomson Reuters will incorporate Sagient,s assessments, ... Forecast Module of Thomson Pharma(R) Partnering ... Forecast Module , in beta testing now ...
... , BETHESDA, Md., July 15 The American Medical ... comments to the Office of the National Coordinator (ONC) and the ... The HIT Policy Committee and its Certification/Adoption Workgroup is meeting and ... , , Dr. Ted Shortliffe, ...
Cached Biology Technology:New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix 2New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix 3Thomson Reuters Partners With Sagient Research 2American Medical Informatics Association (AMIA) Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certification 2
(Date:10/17/2014)... German . ... When treating overdoses, doctors are often limited to supportive therapy ... is a combination of drugs involved. So what can be ... grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute of ... to this question. "The task was to develop an agent ...
(Date:10/16/2014)... Although monocultures can be cultivated efficiently, they are ... water caused by monoculture cultivation is becoming increasingly ... principal crop form and are regarded as the ... production – quite wrongfully, finds Bernhard Schmid, an ... advocates a novel form of agriculture and forestry. ...
(Date:10/15/2014)... to assess the pandemic risk from strains of influenza ... not allow ourselves to become complacent that the most ... of scientists. , Influenza pandemics arise when a new ... develop widespread immunity – spreads in the human population. ... 100 years, the worst of which – the 1918 ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... R. Rodney Howell, MD, FACMG, is the recipient of ... Achievement Award. Dr. Howell is Professor of Pediatrics and ... University of Miami. Dr. Howell, president of the American ... commitment and work in the field of pediatrics and genetic ...
... A new study has estimated that over 260,000 cats and dogs ... full year since the onset of the UK recession. ... of cats and dogs, currently being cared for by UK welfare ... capacity and the number entering these organisations during a 12-month period. ...
... On March 29, 2012, the National Science Foundation ... Coalition for National Science Funding and hosted by the ... Holt (NJ-12) and Judy Biggert (IL-13) and special guests ... "For 60 years, NSF has played a central ...
Cached Biology News:Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 2Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 3Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 4Are we really a nation of animal lovers? 2Science means innovation 2Science means innovation 3
... Analysis Note: The kit contains all the ... determination of NADPH-cytochrome c reductase activity in ... microsomes [endoplastic reticulum (ER)]. It has been ... such as liver, kidney, brain, spleen, and ...
... Strain Competent Cell Sets Sets of ... combinations The most common method ... coli is to use chemically competent ... in the laboratory, greater efficiency, reproducibility and ...
The Saturn 2200 answers your GC/MS questions with the CP-3800 GC and the 2000 Series Ion Trap MS! These components create a platform for the worlds most versatile GC and flexible MS. Both deliver une...
... DNA Methylation Kit uses a simplified procedure ... methylation analysis. The kit is based on ... between cytosine and sodium bisulfite where cytosine ... Methylation Kits innovative in-column desulphonation reaction eliminates ...
Biology Products: